Peptides for Sleep
Research overview of peptides studied for sleep, insomnia, and circadian regulation. DSIP, selank, and sleep-related peptide evidence.
Research Overview
Sleep-related peptide research includes compounds that may influence sleep architecture, circadian rhythm, and stress-related sleep disturbances. Delta sleep-inducing peptide (DSIP) was among the first peptides studied specifically for sleep effects, though its mechanisms remain incompletely understood.
More recent research has explored anxiolytic peptides like selank and semax that may indirectly support sleep through stress reduction. The pineal peptides (epithalon, pinealon) are theorized to influence melatonin production, though human evidence is limited.
Most sleep peptides lack the rigorous clinical trial data that characterizes approved sleep medications. Researchers interested in this area should note the significant gap between preclinical observations and clinical validation.
Key Peptides in Sleep Research
Delta Sleep-Inducing Peptide (DSIP)
Status: Not approved by any regulatory agency
| Aspect | Details |
|---|---|
| Discovery | Identified in rabbit brain, 1977 |
| Mechanism | Poorly characterized |
| Evidence | Low (inconsistent results) |
| Clinical trials | Limited, outdated |
DSIP was one of the first peptides studied specifically for sleep induction, but results have been inconsistent and research has declined.
Selank
Status: Approved in Russia as anxiolytic
| Aspect | Details |
|---|---|
| Mechanism | Tuftsin analog, anxiolytic |
| Sleep effects | Secondary to anxiety reduction |
| Evidence | Low-Moderate |
May support sleep indirectly through anxiolytic effects rather than direct sleep induction.
Pineal Peptides
Epithalon and pinealon are theorized to support circadian rhythm through pineal gland effects, though direct sleep evidence is limited.
Evidence Limitations
- DSIP research largely dates to 1980s-1990s
- Most sleep peptides lack Phase 3 trials
- Mechanisms often poorly characterized
- Quality evidence lags behind approved sleep aids
Peptides Studied for Sleep
Semaglutide
HighA GLP-1 receptor agonist with US approvals that differ by product and route: diabetes products for type 2 diabetes, Wegovy for weight and cardiovascular risk reduction, and Wegovy injection under accelerated approval for noncirrhotic MASH with F2-F3 fibrosis in adults.
Tirzepatide
HighA dual GIP/GLP-1 receptor agonist with US product-specific approvals: Mounjaro for type 2 diabetes in adults and children aged 10 years and older, and Zepbound for adult weight reduction and moderate-to-severe obstructive sleep apnea in adults with obesity. SURPASS-CVOT established cardiovascular noninferiority to dulaglutide, without superiority.
Alixorexton
ModerateAn oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
CJC-1295
ModerateA synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Hexarelin
ModerateThe most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
Ipamorelin
ModerateA growth hormone secretagogue that stimulates GH release without significant effects on cortisol or prolactin. Developed by Novo Nordisk (Denmark); limited clinical development despite promising early data.
Oveporexton
ModerateA first-in-class oral orexin receptor 2 (OX2R) selective agonist developed by Takeda for narcolepsy type 1. Though not a peptide itself, oveporexton restores orexin peptide signaling lost due to autoimmune destruction of orexin-producing neurons. A Phase 2 trial (NEJM 2025) demonstrated significant reductions in excessive daytime sleepiness and cataplexy; Phase 3 trials are ongoing. Granted FDA Breakthrough Therapy designation.
Sermorelin
ModerateA GHRH analog that was FDA-approved for pediatric GH deficiency. Now discontinued commercially but established safety and efficacy profile exists.
Epithalon
LowEpitalon (Ala-Glu-Asp-Gly, AEDG) has produced telomere-related changes in cultured human cells, including a 2025 independent laboratory report. Those experiments do not show longer human life or safe clinical use; controlled human efficacy and exposure data remain unavailable.
MK-677
LowMK-677 (ibutamoren, now also studied as LUM-201) is an investigational oral, non-peptide growth-hormone secretagogue. Human studies establish GH and IGF-1 effects, but clinical benefits for strength, function, cognition, or general anti-aging are not established; pediatric growth-hormone-deficiency trials remain an active research program.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.